BAGSVAERD, Denmark - Pharmaceutical manufacturer Novo Nordisk announced Phase 3 results on Nov. 14 showing its dual therapy CagriSema achieved an average 21% weight reduction.
What happened?
Clinical oncology and endocrinology researchers presented primary outcomes from the REDEFINE 9 clinical trial at the ObesityWeek 2026 conference in Washington, with findings appearing simultaneously in The Lancet Diabetes & Endocrinology. The double-blind trial evaluated CagriSema, an investigational fixed-dose combination combining the glucagon-like peptide-1 analog semaglutide with the long-acting amylin analog cagrilintide. Adult trial participants living with overweight or obesity achieved an average weight loss of approximately 21% at lower maintenance doses while experiencing meaningful reductions in glycated hemoglobin concentrations across active intervention windows.
Why does it matter?
REDEFINE 9 represents the first pivotal late-stage study evaluating dual GLP-1 and amylin co-administration for chronic metabolic disorders. "Novo's investigational CagriSema, a GLP-1 and amylin analog, demonstrated 21% average weight loss with lower doses in the REDEFINE 9 trial," clinical trial directors confirmed in an official regulatory study summary. Demonstrating high therapeutic efficacy at lower dosage levels reduces gastrointestinal tolerability complications, strengthening Novo Nordisk's competitive position within the rapidly expanding global biopharmaceutical anti-obesity market.
What comes next?
Novo Nordisk plans to assemble comprehensive safety registries across its broader REDEFINE development portfolio before submitting a new drug application to the Food and Drug Administration in early 2027. European regulatory teams intend to file marketing authorization submissions with the European Medicines Agency throughout mid-2027. Clinical investigators plan to present comprehensive extended cardiometabolic registry analyses at major international diabetes congresses scheduled across Europe and North America throughout 2027.



